Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.54 |
| ▸ | MME | P08473 | 7/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538262 | 0.94 | LPAR1 (0.53) | ACEMMELPAR1NAALAD2CPA1 | |
| SCHEMBL6895388 | 0.94 | LPAR1 (0.53) | ACEMMELPAR1NAALAD2CPA1 | |
| SCHEMBL6891317 | 0.94 | LPAR1 (0.53) | ACEMMELPAR1NAALAD2CPA1 | |
| SCHEMBL6895621 | 0.92 | MME (0.57) | ACEMMELPAR1CPA1ACE2 | |
| SCHEMBL7051183 | 0.89 | ALDH1A1 (0.55) | ACEMMELPAR1CPA1ACE2 | |
| SCHEMBL27538344 | 0.89 | LPAR1 (0.48) | ACEMMELPAR1CPA1ACE2 | |
| SCHEMBL6890555 | 0.89 | LPAR1 (0.48) | ACEMMELPAR1CPA1ACE2 | |
| SCHEMBL27559954 | 0.88 | PPARG (0.56) | ACEMMECPA1ACE2 | |
| SCHEMBL6898401 | 0.88 | PPARG (0.56) | ACEMMECPA1ACE2 | |
| SCHEMBL6893733 | 0.86 | LPAR1 (0.56) | ACEMMELPAR1NAALAD2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | ACE 1063/4885MME 1516/4885LPAR1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.